22.80

3.26% 0.7241

Syndax Pharmaceuticals Inc (SNDX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$22.08

Offen:

$22.38

24-Stunden-Volumen:

1.13M

Relative Volume:

0.62

Marktkapitalisierung:

$2.02B

Einnahmen:

$217.42M

Nettoeinkommen (Verlust:

$-243.25M

KGV:

-8.1583

EPS:

-2.7952

Netto-Cashflow:

$-278.35M

1W Leistung:

+4.30%

1M Leistung:

+31.49%

6M Leistung:

+3.12%

1J Leistung:

+161.17%

1-Tages-Spanne:

$22.04

$23.08

1-Wochen-Bereich:

$20.70

$23.08

52-Wochen-Spanne:

$8.71

$25.59

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Firmenname

Syndax Pharmaceuticals Inc

Sektor

Healthcare (1100)

Branche

Biotechnology (615)

Telefon

781-419-1400

Adresse

730 THIRD AVENUE, NEW YORK, MA

Mitarbeiter

298

Twitter

@syndax

Nächster Verdiensttermin

2026-08-03

Neueste SEC-Einreichungen

SNDX's Discussions on Twitter

Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SNDX Syndax Pharmaceuticals Inc	22.80	1.93B	217.42M	-243.25M	-278.35M	-2.7952
VRTX Vertex Pharmaceuticals Inc	524.24	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.56	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	921.42	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.37	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	191.67	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-16	Fortgesetzt	H.C. Wainwright	Buy
2025-09-10	Fortgesetzt	Stifel	Buy
2025-09-04	Fortgesetzt	Guggenheim	Buy
2025-08-05	Bestätigt	BTIG Research	Buy
2025-07-10	Eingeleitet	Goldman	Buy
2024-10-24	Eingeleitet	UBS	Buy
2024-06-28	Eingeleitet	Jefferies	Buy
2024-01-31	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2023-12-22	Eingeleitet	Mizuho	Buy
2023-10-25	Eingeleitet	BofA Securities	Buy
2023-10-11	Eingeleitet	Goldman	Buy
2023-07-27	Eingeleitet	Scotiabank	Sector Outperform
2023-07-11	Eingeleitet	Guggenheim	Buy
2023-04-17	Fortgesetzt	BTIG Research	Buy
2023-01-31	Eingeleitet	Stifel	Buy
2023-01-03	Eingeleitet	JP Morgan	Overweight
2022-07-28	Fortgesetzt	B. Riley Securities	Buy
2022-04-11	Eingeleitet	H.C. Wainwright	Buy
2022-02-15	Eingeleitet	Goldman	Buy
2021-06-04	Fortgesetzt	Robert W. Baird	Outperform
2021-05-25	Eingeleitet	Citigroup	Buy
2021-02-18	Eingeleitet	B. Riley Securities	Buy
2020-12-03	Eingeleitet	Stifel	Buy
2020-05-22	Hochstufung	Citigroup	Neutral → Buy
2020-05-22	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-05-18	Herabstufung	Citigroup	Buy → Neutral
2020-05-11	Bestätigt	H.C. Wainwright	Buy
2020-03-04	Eingeleitet	Barclays	Overweight
2020-01-13	Bestätigt	H.C. Wainwright	Buy
2019-03-08	Bestätigt	H.C. Wainwright	Buy
2019-01-04	Eingeleitet	Robert W. Baird	Outperform
2018-01-05	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-03-16	Eingeleitet	FBR & Co.	Outperform
2017-03-02	Eingeleitet	Instinet	Buy
2016-10-07	Eingeleitet	Guggenheim	Buy
2016-03-28	Eingeleitet	Citigroup	Buy
2016-03-28	Eingeleitet	JMP Securities	Mkt Outperform
2016-03-28	Eingeleitet	Morgan Stanley	Overweight

Alle ansehen

Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten

08:27 AM

Syndax Pharmaceuticals holds steady as investors await a fresh catalyst - AD HOC NEWS

08:27 AM

Jul 06, 2026

SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat

Jul 06, 2026

Jul 01, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Jul 01, 2026

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire

Jul 01, 2026

Syndax Pharmaceuticals (NASDAQ:SNDX) Draws Fresh Market Attention - Kalkine Media

Jul 01, 2026

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat

Jul 01, 2026

Jun 30, 2026

Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Insider Monkey

Jun 30, 2026

Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView

Jun 30, 2026

Jun 29, 2026

Price to sales forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView

Jun 29, 2026

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 29, 2026

Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 29, 2026

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative? - simplywall.st

Jun 28, 2026

Enterprise value to EBITDA forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 28, 2026

Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily

Jun 28, 2026

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com

Jun 28, 2026

Price to earnings forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 28, 2026

Price to earnings forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

Jun 28, 2026

Enterprise value to revenue forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView

Jun 28, 2026

Price to book forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView

Jun 28, 2026

Jun 27, 2026

H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo

Jun 25, 2026

1T3 Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Jun 23, 2026

Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data - Sahm

Jun 23, 2026